novo nordisk responds to illegal online sales of semaglutide: actively supports the government to take effective law enforcement actions
2024-09-19
한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina
novo nordisk visual china data map
on september 18, the website of the state food and drug administration announced four typical cases of illegal and irregular drug sales online (the sixth batch), including several cases of illegal sales of semaglutide or drugs containing semaglutide through the internet.
the original manufacturer of semaglutide is the danish pharmaceutical company novo nordisk. regarding the management of semaglutide sales channels, novo nordisk told the paper on september 19 that, as of now, the company's only semaglutide product approved and commercially launched in china is novotec, and the approved indication is adult type 2 diabetes. in china, novo nordisk sells prescription drugs in strict accordance with the requirements of laws and regulations, and only cooperates with distributors with pharmaceutical business qualifications. as of now,novo nordisk has not sold novotac on any online platform (including e-commerce, social platforms, etc.), nor has it authorized or commissioned any third party to sell the drug on the online platform.。
novo nordisk emphasized that in china, in addition to strictly following the requirements of laws and regulations to sell and manage prescription drugs, novo nordisk also actively monitors the production and sales of potential counterfeit, infringing and other illegal drugs sold or circulated in the market, and actively supports government regulators to take effective law enforcement actions. novo nordisk has always been committed to ensuring patient safety and will continue to support government regulators in taking legal action against entities suspected of engaging in similar illegal activities.
semaglutide is a star product of glp-1 drugs in the world. it has been approved for indications such as diabetes and weight loss, and was once in short supply. the weight loss indication of semaglutide was officially approved in china in june this year. it is the world's first and currently the only glp-1 weekly preparation for long-term weight management. while it has become popular around the world, semaglutide has also encountered many chaos in sales. three of the four cases reported by the state drug administration on the 18th involved semaglutide or drugs containing semaglutide.
specifically, in april 2023, based on clues from complaints and reports, the taizhou municipal market supervision administration of zhejiang province and the public security organs conducted an inspection around a hospital in taizhou city and found that the party involved, peng moumou, sold drugs such as semaglutide injection through the china medical supply and demand network, china drug sales network and wechat groups without obtaining a drug business license. the value of the goods involved was 127,500 yuan. the above-mentioned behavior of the party violated the provisions of article 51, paragraph 1 of the "drug administration law of the people's republic of china". in september 2023, the taizhou jiaojiang district market supervision administration imposed administrative penalties on the party involved in accordance with article 115 of the "drug administration law of the people's republic of china", including confiscation of the drugs involved, confiscation of illegal gains of 117,600 yuan, and a fine of 2.5504 million yuan.
in september 2023, based on clues found in routine supervision, the guangdong provincial drug administration and the public security organs conducted special inspections in guangzhou, nanchang, yingtan and other places, and found that the parties ye, zhan, gao and others purchased raw materials through wechat, alibaba, pinduoduo and other online platforms, and produced and sold weight loss drugs containing semaglutide without obtaining drug production licenses and drug business licenses. the value of the goods involved reached 35 million yuan. in november 2023, the guangzhou municipal market supervision administration transferred the case to the public security organs in accordance with the provisions of article 142 of the criminal law of the people's republic of china.
in january 2024, the tongling municipal market supervision administration of anhui province inspected the "kangmei shiseido women's skin care store" in wusong town and found that wan and chen sold injections containing semaglutide without chinese labels through wechat without obtaining a drug business license. the drugs involved did not obtain relevant drug approval documents, and the amount involved by wan and chen exceeded 10 million yuan. in february 2024, the tongling municipal market supervision administration transferred the case to the public security organs in accordance with article 142 of the criminal law of the people's republic of china.
the state food and drug administration also reminds that drugs such as semaglutide, liraglutide, and telpotide are prescription drugs for the treatment of diabetes. some varieties are approved for the treatment of obesity and overweight, but the applicable population is strictly limited. the use of such drugs should be diagnosed by a doctor, purchased from formal channels with a prescription, and used reasonably under the guidance of professionals. if people who are not in the applicable population choose to use the drugs on their own, it may cause serious adverse gastrointestinal reactions and cause damage to their health; if such drugs are purchased and used from informal channels, or if related products that are not approved (claiming to contain similar ingredients) are purchased and used, there may be quality problems such as unknown ingredients, inaccurate measurements, and adulteration, which cannot guarantee the treatment effect and may also cause serious toxic reactions and threaten life safety.
li xiaoxiao, reporter from the paper
(this article is from the paper. for more original information, please download the "the paper" app)
